Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.
Malignant lymphomas.
Hematology; 14:299-334 1991. Unique Identifier : AIDSLINE ICDB/93689059 Cabanillas F; UT M.D. Anderson Cancer Center, Houston, TX 77030
Abstract:
The malignant lymphomas are a group of heterogeneous disorders that cover a wide range of clinical behaviors. Two fundamental requirements for the management of lymphomas are (1) appropriate pathological classification and (2) good understanding of the natural history of the various cell types. Characteristics and management of malignant lymphomas are reviewed, including staging and restaging; low-grade lymphoma (LGL: management of Ann Arbor Stage I-II presentations of LGL, management of Ann Arbor Stage III LGL, management of Ann Arbor Stage IV LGL); intermediate-grade lymphomas (treatment of Stage I-II large-cell lymphoma, Stage III-IV large-cell lymphoma, and diffuse mixed and diffuse small cleaved cell lymphoma); high-grade lymphomas (diffuse small noncleaved cell lymphoma and lymphoblastic lymphoma); management of complicated situations (superior vena cava syndrome, spinal cord compression, CNS lymphoma, and recurrent and refractory lymphoma); new histological entities (Ki-1 lymphoma); and future perspectives (polymerase chain reaction and multidrug resistance). Despite a recent Southwest Oncology Group study indicating otherwise, most single-institution studies point toward a consistent improvement in prognosis of intermediate- and high-grade lymphomas during the past decade. A better understanding of the natural history, as well as the increasing knowledge about the biology of these disorders, should guide future efforts in managing them. The HIV-related lymphoma remains an area for which new ideas are needed. The opportunistic infections frequently seen in these patients (pts), whose absolute T4 lymphocyte count is fewer than 100, are a formidable challenge for their management. The occurrence of Kaposi's sarcoma in pts who have been cured of their lymphoma also is a problem. Currently, the most pressing challenge is the treatment of pts with Stage IV, low-grade lymphoma in whom the natural history of the disease is characterized by a steady and continuous relapse pattern. However, these disorders exhibit great sensitivity to chemotherapy. (88 Refs)
Keywords: Bleomycin/THERAPEUTIC USE Bone Marrow Transplantation Central Nervous System Neoplasms/DIAGNOSIS/THERAPY Cyclophosphamide/THERAPEUTIC USE Cytarabine/THERAPEUTIC USE Doxorubicin/THERAPEUTIC USE Etoposide/THERAPEUTIC USE Human Ifosfamide/THERAPEUTIC USE Lymphoma/DRUG THERAPY/PATHOLOGY/SURGERY Lymphoma, Diffuse/THERAPY Lymphoma, Large-Cell/PATHOLOGY/THERAPY Lymphoma, Lymphoblastic/THERAPY Mechlorethamine/THERAPEUTIC USE Methotrexate/THERAPEUTIC USE Mitoguazone/THERAPEUTIC USE Neoplasm Recurrence, Local Polymerase Chain Reaction Prednisolone/THERAPEUTIC USE Prednisone/THERAPEUTIC USE Procarbazine/THERAPEUTIC USE Spinal Cord Compression/COMPLICATIONS/THERAPY Superior Vena Cava Syndrome/COMPLICATIONS/THERAPY Vincristine/THERAPEUTIC USE MONOGRAPH
930530
M9350987
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.
